Ali Tayebi Meybodi1, Helen Kim2,3, Jeffrey Nelson2,3, Steven W Hetts4,3, Timo Krings5, Karel G terBrugge5, Marie E Faughnan6, Michael T Lawton1,2,3. 1. Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. 2. Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, California. 3. Center for Cerebrovascular Research, University of California, San Francisco, San Francisco, California. 4. Division of Neurointerventional Radiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California. 5. Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 6. Division of Respirology, Keenan Research Centre, and Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Cerebral arteriovenous malformations (AVMs) are common in patients with hereditary hemorrhagic telangiectasia (HHT). However, due to the rarity of HHT and little published evidence of outcomes from management of brain AVMs in this disease, current international HHT guidelines recommend an individualized approach. Specifically, the outcomes for surgical vs nonsurgical management of these lesions have not been reported to date. OBJECTIVE: To report long-term outcomes of surgical resection of brain AVMs in HHT patients compared to outcomes in nonsurgically treated patients. METHODS: From the database of the Brain Vascular Malformation Consortium HHT project, 19 patients with 20 resected AVMs (group 1) and 22 patients with 33 AVMs who received nonsurgical treatment (group 2) were studied. The groups were retrospectively reviewed for changes in functional status (modified Rankin Scale score) during the follow-up period. RESULTS: During the follow-up period, 9% of patients in group 1 suffered from worsening of functional status, whereas this figure was 16% for group 2 (P > .05). Functional outcomes were not statistically different between the 2 groups at the latest follow-up (P > .05). CONCLUSION: HHT patients treated surgically for brain AVMs appear to have long-term functional outcomes comparable to nonsurgical (including observational) therapy with fewer unfavorable outcomes. It is therefore reasonable to consider surgical resection as a management option in the multidisciplinary team's individualized treatment strategy for HHT patients with brain AVMs.
BACKGROUND:Cerebral arteriovenous malformations (AVMs) are common in patients with hereditary hemorrhagic telangiectasia (HHT). However, due to the rarity of HHT and little published evidence of outcomes from management of brain AVMs in this disease, current international HHT guidelines recommend an individualized approach. Specifically, the outcomes for surgical vs nonsurgical management of these lesions have not been reported to date. OBJECTIVE: To report long-term outcomes of surgical resection of brain AVMs in HHTpatients compared to outcomes in nonsurgically treated patients. METHODS: From the database of the Brain Vascular Malformation Consortium HHT project, 19 patients with 20 resected AVMs (group 1) and 22 patients with 33 AVMs who received nonsurgical treatment (group 2) were studied. The groups were retrospectively reviewed for changes in functional status (modified Rankin Scale score) during the follow-up period. RESULTS: During the follow-up period, 9% of patients in group 1 suffered from worsening of functional status, whereas this figure was 16% for group 2 (P > .05). Functional outcomes were not statistically different between the 2 groups at the latest follow-up (P > .05). CONCLUSION:HHTpatients treated surgically for brain AVMs appear to have long-term functional outcomes comparable to nonsurgical (including observational) therapy with fewer unfavorable outcomes. It is therefore reasonable to consider surgical resection as a management option in the multidisciplinary team's individualized treatment strategy for HHTpatients with brain AVMs.
Authors: S Matsubara; J L Mandzia; K ter Brugge; R A Willinsky; M E Faughnan; J L Manzia Journal: AJNR Am J Neuroradiol Date: 2000 Jun-Jul Impact factor: 3.825
Authors: A J Easey; G M F Wallace; J M B Hughes; J E Jackson; W J Taylor; C L Shovlin Journal: J Neurol Neurosurg Psychiatry Date: 2003-06 Impact factor: 10.154
Authors: Rose Du; Tomoki Hashimoto; Tarik Tihan; William L Young; Victor Perry; Michael T Lawton Journal: J Neurosurg Date: 2007-03 Impact factor: 5.115
Authors: Juha A Hernesniemi; Reza Dashti; Seppo Juvela; Kristjan Väärt; Mika Niemelä; Aki Laakso Journal: Neurosurgery Date: 2008-11 Impact factor: 4.654
Authors: J P Mohr; Michael K Parides; Christian Stapf; Ellen Moquete; Claudia S Moy; Jessica R Overbey; Rustam Al-Shahi Salman; Eric Vicaut; William L Young; Emmanuel Houdart; Charlotte Cordonnier; Marco A Stefani; Andreas Hartmann; Rüdiger von Kummer; Alessandra Biondi; Joachim Berkefeld; Catharina J M Klijn; Kirsty Harkness; Richard Libman; Xavier Barreau; Alan J Moskowitz Journal: Lancet Date: 2013-11-20 Impact factor: 79.321
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: M S Perez Akly; C Vazquez; C H Besada; M J Rodriguez; M F Conde; A R Cajal; V A Peuchot; D Dardik; M M Baccanelli; M M Serra Journal: AJNR Am J Neuroradiol Date: 2022-05-19 Impact factor: 4.966
Authors: K P Thompson; J Nelson; H Kim; S M Weinsheimer; D A Marchuk; M T Lawton; T Krings; M E Faughnan Journal: Orphanet J Rare Dis Date: 2021-09-19 Impact factor: 4.123